Major Growth Driver Identified in 2025 Prescription Orthopedic Drugs Market: Rising Prevalence Of Musculoskeletal Disorders Driving Demand For Treatment Solutions

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Prescription Orthopedic Drugs Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
There has been firm growth in the prescription orthopedic drugs market size in the past few years. The market is expected to expand from $48.41 billion in 2024 to $51.06 billion in 2025, flourishing at a compound annual growth rate (CAGR) of 5.5%. Factors such as the heightened occurrence of musculoskeletal disorders, the surge in the elderly populace, the rising consciousness of osteoporosis therapies, increasing healthcare reach in emergent areas, and globally escalating sports-associated injuries have contributed to the growth during the historic period.

Prescription Orthopedic Drugs Market Size Forecast: What's the Projected Valuation by 2029?
In the coming years, the market size for prescription orthopedic drugs is predicted to experience significant growth, reaching "$63.86 billion in 2029 with a compound annual growth rate (CAGR) of 5.8%. This projected growth in the market can be credited to factors such as the rising demand for biologics, an increasing elderly population, improved healthcare accessibility in emerging economies, growing occurrence of chronic musculoskeletal disorders, and higher investment in research and development of orthopedic drugs. With respect to the period of the forecast, key trends include the evolution in targeted biologics, the incorporation of regenerative medical treatments, personalized medication compositions, progress in minimally invasive delivery techniques, improved drug efficacy via gene therapy, breakthroughs in injectable formulations, and the introduction of artificial intelligence in drug development and clinical decision-making processes.

View the full report here:
https://www.thebusinessresearchcompany.com/report/prescription-orthopedic-drugs-global-market-report

What Are the Drivers Transforming the Prescription Orthopedic Drugs Market?
The rise in cases of musculoskeletal disorders is set to propel the prescription orthopedic drugs market's expansion in the future. Conditions and injuries that disrupt the functionality and mobility of the body's musculoskeletal system, comprising muscles, tendons, nerves, ligaments, and joints, are known as musculoskeletal disorders (MSDs). They typically result in pain and mobility reduction. The primary contributors to the escalating prevalence of these disorders include lifestyle habits like inadequate physical activity and nutrition, aging, occupational tasks involving repetitious movements and uncomfortable postures, and genetic factors. Prescription orthopedic medications are crucial in treating these disorders as they mitigate pain, suppress inflammation, and speed up healing, which enhances mobility and the overall life quality. For instance, a report by the Office for Health Improvement and Disparities, a public health department based in the UK, in March 2023 stated that a rise from 17.0% in 2021 to 17.6% of people 16 years and older reported continual musculoskeletal issues like arthritis or constant back or joint pain in 2022. Additionally, there were around 1.71 billion musculoskeletal disorder cases globally, as reported by the World Health Organization, a Switzerland-based intergovernmental organization, in July 2022. Consequently, the escalating occurrence of musculoskeletal disorders is steering the prescription orthopedic drugs market's surge.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21263&type=smp

What Trends Will Shape the Prescription Orthopedic Drugs Market Through 2029 and Beyond?
The prescription orthopedic drugs market is seeing a trend of major companies expanding the use of their medications in order to enlarge their market size, improve patient results, and meet the unaddressed healthcare requirements in various orthopedic conditions. A case in point is Heron Therapeutics Inc., an American biotech firm that gained FDA approval in January 2023 for the wider use of ZYNRELEF (a combination of bupivacaine and meloxicam) in orthopedic and soft tissue procedures, encompassing foot and ankle surgeries. Its distinctive design allows for an extended pain relief period of up to 72 hours, negating or reducing post-surgery opioid requirement. The broadened indication covers more orthopedic and soft tissue surgeries, thereby widening its clinical use. The innovative dual-drug mix provides both local anesthetic and anti-inflammatory effects, making it a comprehensive solution for managing post-surgical pain for better patient results.

Which Segments in the Prescription Orthopedic Drugs Market Offer the Most Profit Potential?
The prescription orthopedic drugs market covered in this report is segmented -

1) By Drug Type: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Opioids, Corticosteroids, Disease-Modifying Antirheumatic Drugs (DMARDs), Other Drug Types
2) By Application: Osteoarthritis, Rheumatoid Arthritis, Osteoporosis, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Naproxen, Diclofenac, Celecoxib, Indomethacin
2) By Opioids: Morphine, Oxycodone, Hydrocodone, Fentanyl, Trama*dol
3) By Corticosteroids: Prednisone, Methylprednisolone, Dexamethasone, Hydrocortisone, Betamethasone
4) By Disease-Modifying Antirheumatic Drugs (DMARDs): Methotrexate, Hydroxychloroquine, Leflunomide, Sulfasalazine, Azathioprine
5) By Other Drug Types: Bisphosphonates, Calcitonin, Monoclonal Antibodies, Muscle Relaxants, Hyaluronic Acid Injections

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=21263&type=smp

Which Firms Dominate the Prescription Orthopedic Drugs Market by Market Share and Revenue in 2025?
Major companies operating in the prescription orthopedic drugs market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck KGaA, AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GSK Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Biogen Inc., UCB S.A., Allergan plc, Penardo Biotech Pvt. Ltd., Horizon Therapeutics plc

Which Regions Offer the Highest Growth Potential in the Prescription Orthopedic Drugs Market?
North America was the largest region in the prescription orthopedic drugs market in 2024. The regions covered in the prescription orthopedic drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21263

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.